prostatic hyperplasia (BPH) and normal prostate (NP) tissues were collected for comparison.
INTRODUCTION AND OBJECTIVES: A novel, immunosuppressive B cell subpopulation that accelerated the emergence of castrate resistant prostate cancer (PCa) was uncovered in mouse models and PCa. Murine models have demonstrated delays in PCa regrowth after ablation of B lymphocytes with rituximab. Our objective was to determine whether neoadjuvant treatment of high risk PCa patients could reduce B cell infiltration. We report B cell density in tumor and adjacent tissue for 8 patients with high risk PCa who received neoadjuvant rituximab when compared to 11 historical controls.
METHODS: An open label, non-randomized, single arm clinical trial for high risk PCa prior to prostatectomy ( 00 PROTUX 00 NCT01804712). Inclusion criteria were nomogram 5-year disease free prediction < 60% or Gleason sum 8, ECOG of 0-1. Subjects were candidates for prostatectomy with curative intent. Exclusion criteria were any prior treatment for PCa, metastatic disease, history of hepatitis B or C, HIV, tuberculosis, or chronic infections. Enrolled men received one cycle of rituximab (375 mg/m2 IV once weekly for 28 days), followed in 2 weeks by prostatectomy. Controls were selected from a pathologic biobank with similar patient characteristics and stained concurrently for CD20. Tumor regions were marked by a blinded pathologist and a computer algorithm quantified the immunofluorescence in tumor and adjacent tissue regions. First, mean B-cell fluorescence within the tumor was compared against historical controls. Then mean within patient difference (fluorescence tumor -fluorescence adjacent tissue) was compared against controls, both utilizing unequal variances t test. RESULTS: Treated and control groups were similar in age, BMI, mean PSA at diagnosis. The treatment group experienced 10 adverse events with 4 likely related to treatment ( grade2), with 1 serious adverse event being a pulmonary embolism, deemed unrelated to treatment. Mean CD20 fluorescence intensity in the tumor region of the untreated and treated groups was 0.044 (95% CI 0.028 -0.062) and 0.027 (95% CI 0.021 -0.033) p¼0.02, respectively. Mean within patient difference of CD20 fluorescence was 0.009 (95% CI -0.004 -0.023) and -0.005 (95% CI -0.028 -0.017) (p¼0.11) in the untreated and treated groups, respectively. CONCLUSIONS: Rituximab significantly decreased B cell concentration within tumors compared to historical controls and appeared to reduce the concentration of tumor resident B cells to levels comparable to adjacent normal tissue, (p¼0.11 relative to controls). These results provide evidence that rituximab can modify the immune environment of the tumor. 
MP71-01 VARIATION IN TREATMENT OF MUSCLE INVASIVE BLADDER CANCER ASSOCIATED WITH AGE, COMORBIDITY, AND LIFE EXPECTANCY
Devin Patel*, Michael Luu, Zachary Zumsteg, Maurice Garcia, Timothy Daskivich, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Current guidelines endorse using age and comorbidity in treatment decision making for muscle-invasive bladder cancer (MIBC), but the impact of each on treatment is unknown. We aimed to investigate variation in treatment for MIBC across differing ages and comorbidity burdens at diagnosis.
METHODS: A retrospective study of 19,228 patients with newly diagnosed MIBC between 2004-2012 from the National Cancer Data Base was performed. We measured rates of utilization of curative therapy, with either radical cystectomy (RC) or bladder sparing therapy (partial cystectomy þ/-chemotherapy or RT >45 Gy þ/-chemotherapy) across age and Charlson comorbidity index (CCI) subgroups. Multivariable logistic regression was used to determine the association of age and comorbidity with RC, bladder sparing therapy, and curative therapy.
RESULTS: Use of RC decreased with older age but not with comorbidity. In multivariable analysis, patients aged 60-69 (OR0.89; p¼0.028), [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] p<0.001), [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] p<0.001) and >90 (OR0.03; p<0.001) were significantly less likely to receive RC compared with those <60. In contrast, those with CCI 1 (OR1.13; p¼0.001) and 2þ (OR0.9; p¼0.08) were not less likely to receive RC compared with those with CCI 0. Trends for use of curative therapy mirrored those of RC. Bladder sparing therapy was used infrequently, more often with older age but not comorbidity. In multivariable analysis, patients aged 70-79 (OR1.3; p¼0.006) and 80-89 (OR1.9; p<0.001) had significantly higher odds of bladder sparing compared with those <60. Those with CCI 1 (OR0.99; p¼0.8) and 2þ (OR1.05; p¼0.6) were no more likely to receive bladder sparing than those with CCI 0. Study limitations include inability to capture all variables influencing treatment selection.
CONCLUSIONS: Comorbidity is poorly integrated into treatment decision making for MIBC, leading to overtreatment and undertreatment based on life expectancy as well as underutilization of bladder-sparing therapy in older, sicker patients.
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